Belite Bio CSO sells 666 ADS in planned trades

Belite Bio Chief Scientific Officer Nathan L. Mata sold shares of the company in pre-planned trades.

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata sold shares of the company in pre-planned trades. On May 7, 2026, he executed four open-market sales totaling 666 American depositary shares at prices ranging from about $152 to $155 per share.

Each American depositary share represents one ordinary share of Belite Bio. The sales were made under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following these transactions, Mata reported no American depositary shares held directly and no remaining derivative positions in this filing.

Insider Trade Summary 10b5-1

Net Seller: 666 shares

Net Sell 4 txns

Insider MATA NATHAN L.

Role Chief Scientific Officer

Sold 666 shs ($102K)

Type	Security	Shares	Price	Value
Sale	American depositary share	226	$152.4473	$34K
Sale	American depositary share	428	$153.5635	$66K
Sale	American depositary share	3	$154.61	$463.83
Sale	American depositary share	9	$155.2533	$1K

Holdings After Transaction: American depositary share — 0 shares (Direct)

Footnotes (5)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. F3. Represents the weighted average price of shares sold at prices that ranged from $152.35 to $152.68. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. F4. Represents the weighted average price of shares sold at prices that ranged from $153.1 to $153.92. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. F5. Represents the weighted average price of shares sold at prices that ranged from $155.18 to $155.29. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

Total shares sold: 666 American depositary shares Largest trade size: 428 American depositary shares Representative sale price: $153.5635 per share +4 more

7 metrics

Total shares sold 666 American depositary shares Aggregate open-market sales on May 7, 2026

Largest trade size 428 American depositary shares Single transaction at $153.5635 per share

Representative sale price $153.5635 per share 428-share open-market sale on May 7, 2026

Highest reported sale price $155.2533 per share 9-share open-market sale on May 7, 2026

Shares remaining after trades 0 American depositary shares Direct ownership reported following final sale

Number of sale transactions 4 transactions Open-market sales reported in this Form 4

Net direction Net sale of 666 shares transactionSummary netBuySellShares and direction

Key Terms

American depositary share, Rule 10b5-1 trading plan, weighted average price, open-market sale

4 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001 per share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"Represents the weighted average price of shares sold at prices that ranged from $152.35 to $152.68"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Belite Bio (BLTE) insider Nathan L. Mata report in this Form 4?

Nathan L. Mata, Chief Scientific Officer of Belite Bio, reported selling 666 American depositary shares in four open-market transactions on May 7, 2026. The filing shows these trades were executed under a pre-established Rule 10b5-1 trading plan.

How many Belite Bio (BLTE) shares did the CSO sell and at what prices?

Mata sold a total of 666 American depositary shares at prices around $152–$155 per share. Individual reported transactions included 428 shares at $153.5635, 226 shares at $152.4473, 3 shares at $154.6100, and 9 shares at $155.2533.

Does Nathan L. Mata still hold Belite Bio (BLTE) American depositary shares after these sales?

According to this Form 4, Mata reported 0 American depositary shares directly owned after the final transaction. The derivative section is empty, indicating no remaining derivative positions are shown for him in this particular filing snapshot.

Were the Belite Bio (BLTE) insider sales made under a trading plan?

Yes. A footnote explains the sales were executed under a Rule 10b5-1 trading plan adopted by Mata on December 10, 2025. Such plans typically pre-schedule trades, reducing the significance of short-term market timing for these transactions.

What type of security did the Belite Bio (BLTE) insider sell?

Mata sold American depositary shares (ADS), each representing one ordinary share of Belite Bio. ADSs allow investors to hold interests in non-U.S. companies through securities that trade in U.S. markets, simplifying settlement and custody.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATA NATHAN L.

(Last) (First) (Middle)

7708 MARKER ROAD

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	05/07/2026		S(2)		226	D	$152.4473(3)	440	D
American depositary share(1)	05/07/2026		S(2)		428	D	$153.5635(4)	12	D
American depositary share(1)	05/07/2026		S(2)		3	D	$154.61	9	D
American depositary share(1)	05/07/2026		S(2)		9	D	$155.2533(5)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.

3. Represents the weighted average price of shares sold at prices that ranged from $152.35 to $152.68. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $153.1 to $153.92. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $155.18 to $155.29. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Nathan L. Mata	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)